Jannatul Firdaus
JF-Expert Member
- Aug 4, 2026
- 446
- 1,113
Falme za Kiarabu UAE zimekuwa nchi ya kwanza duniani kuidhinisha matumizi mapya ya dawa ya RINVOQ, katika kutibu vitiligo isiyo ya segmenti, ugonjwa wa ngozi unaosababisha baadhi ya maeneo ya ngozi kupoteza rangi.
Mamlaka ya Dawa ya Falme za Kiarabu, Emirates Drug Establishment (EDE), ilitangaza Jumatatu kuwa imeidhinisha matumizi ya dawa hiyo kutibu vitiligo isiyo ya segmenti kwa watu wazima na vijana wenye umri wa miaka 12 na zaidi ambao hali yao inahitaji matibabu ya kimfumo, yaani dawa zinazosambazwa mwilini kupitia mfumo wa damu.
Kwa mujibu wa Mamlaka ya Dawa ya Falme za Kiarabu, hatua hiyo inaifanya dawa hiyo kuwa dawa ya kwanza ya kumeza iliyoidhinishwa kwa kundi hilo la wagonjwa.
Dawa hiyo hutumiwa kwa kumeza mara moja kwa siku, na hivyo kuongeza chaguo la matibabu kwa wagonjwa wanaokidhi vigezo vya matumizi kwa mujibu wa miongozo ya kitabibu.
Vitiligo ni ugonjwa wa ngozi unaotokea pale seli zinazozalisha rangi ya ngozi zinapoharibika au kuacha kufanya kazi, na kusababisha mabaka meupe au yenye rangi iliyopungua kwenye sehemu mbalimbali za mwili
============
The UAE has become the first country in the world to approve the oral treatment RINVOQ (upadacitinib) for non-segmental vitiligo, a skin condition causing patches of skin to lose colour.
The Emirates Drug Establishment (EDE) approved the treatment, which applies to patients aged 12 years and above whose condition requires systemic therapy through medicines that circulate in the bloodstream.
The medicine is taken orally once a day, providing an additional treatment option for eligible patients in line with approved medical criteria.
It is considered the first licensed oral treatment for non-segmental vitiligo patients, considered the most common form of the skin condition that appears in symmetric areas across the body.
Meanwhile, segmental vitiligo, seen in fewer cases, is focused towards one patch or area within the patient affected.
The medication provides an additional option for eligible patients, expanding the scope of treatment in the UAE and worldwide.
The establishment urged the public to consult a specialist if they notice any unusual changes in skin colour, to support early diagnosis, proper assessment, and the selection of the most appropriate treatment for each patient.
Source: ARN NEWS CENTRE
Mamlaka ya Dawa ya Falme za Kiarabu, Emirates Drug Establishment (EDE), ilitangaza Jumatatu kuwa imeidhinisha matumizi ya dawa hiyo kutibu vitiligo isiyo ya segmenti kwa watu wazima na vijana wenye umri wa miaka 12 na zaidi ambao hali yao inahitaji matibabu ya kimfumo, yaani dawa zinazosambazwa mwilini kupitia mfumo wa damu.
Kwa mujibu wa Mamlaka ya Dawa ya Falme za Kiarabu, hatua hiyo inaifanya dawa hiyo kuwa dawa ya kwanza ya kumeza iliyoidhinishwa kwa kundi hilo la wagonjwa.
Dawa hiyo hutumiwa kwa kumeza mara moja kwa siku, na hivyo kuongeza chaguo la matibabu kwa wagonjwa wanaokidhi vigezo vya matumizi kwa mujibu wa miongozo ya kitabibu.
Vitiligo ni ugonjwa wa ngozi unaotokea pale seli zinazozalisha rangi ya ngozi zinapoharibika au kuacha kufanya kazi, na kusababisha mabaka meupe au yenye rangi iliyopungua kwenye sehemu mbalimbali za mwili
============
The UAE has become the first country in the world to approve the oral treatment RINVOQ (upadacitinib) for non-segmental vitiligo, a skin condition causing patches of skin to lose colour.
The Emirates Drug Establishment (EDE) approved the treatment, which applies to patients aged 12 years and above whose condition requires systemic therapy through medicines that circulate in the bloodstream.
The medicine is taken orally once a day, providing an additional treatment option for eligible patients in line with approved medical criteria.
It is considered the first licensed oral treatment for non-segmental vitiligo patients, considered the most common form of the skin condition that appears in symmetric areas across the body.
Meanwhile, segmental vitiligo, seen in fewer cases, is focused towards one patch or area within the patient affected.
The medication provides an additional option for eligible patients, expanding the scope of treatment in the UAE and worldwide.
The establishment urged the public to consult a specialist if they notice any unusual changes in skin colour, to support early diagnosis, proper assessment, and the selection of the most appropriate treatment for each patient.
Source: ARN NEWS CENTRE
